扩张型心肌病患者应用左西孟旦临床疗效研究

Clinical Study on Levosimendan in Patients With Dilated Cardiomyopathy

目的观察不同年龄段的扩张型心肌病(DCM)患者应用左西孟旦后的临床疗效。方法选择2016-01/2017-05在四川省人民医院心衰中心住院治疗诊断为扩张型心肌病患者33例,从年龄、性别等角度分析该药物与心衰治疗的关系。对比分析应用左西孟旦治疗前后的B型利钠肽(BNP水平)、左室射血分数(LVEF)和相关临床指标。结果与治疗前比,不同年龄、性别组应用左西孟旦后LVEF均有提高,差异有统计学意义(P<0.05)。尿酸水平均有下降,中青年组及男性组差异有统计学意义(P<0.05),老年组及女性组差异无统计学意义(P>0.05)。患者治疗前后血钠水平差异无统计学意义(P>0.05)。与治疗前比,左西孟旦治疗后中不同年龄、性别组BNP水平差异均有统计学意义(P<0.05),但各组治疗后BNP下降比值差异均无统计学意义(P>0.05)。结论研究提示,左西孟旦治疗扩张型心肌病,短期内对扩心病患者心功能均有改善。

Objective To observe the clinical efficacy of levosimendan in patients with dilated cardiomyopathy （DCM） at different ages. Methods 33 DCM inpatients were selected from Jan 2016 to May 2017 in heart failure center of our hospital. The relationship between the drug and the treatment of heart failure was analyzed from the perspective of age and sex. The levels of B - type natriuretic peptide （ BNP）, left ventricular ejection fraction （LVEF） and related clinical indexes were analyzed before and after treatment with levosimendan. Results Compared with the two age groups and gender groups, before and after application of levosimendam, LVEF was increased significantly in both groups （ P 〈 0.05 ） ; uric acid levels were both decreased. The difference was statistical significance in the young group and male group （P 〈 O. 05 ） , but not in the older - age group and female group; plasma sodium levels showed no significant difference in all groups （P 〉 0. 05 ） ; the difference of BNP levels showed no statistical significance in all groups （ P 〈 O. 05 ）, but there was no sta- tistical significance between BNP changing - rate before and after treatment （ P 〉 0.05 ）. Conclusion Our study found that levosimendan treatment of dilated cardiomyopathy, short - term in young and elderly patients with heart disease can improv heart function.